Driehaus Capital OLMA Position
Exited10-Fund ConvergenceDriehaus Capital exited their position in Olema Pharmaceuticals, Inc. (OLMA) in Q4 2023, after holding the stock for 3 quarters.
The position was first reported in Q2 2023 and has been tracked across 3 quarterly 13F filings.
OLMA is a convergence signal: 10 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Palazestrant in 75 days (Jun 30, 2026), making the timing of Driehaus's position particularly relevant.
Short interest stands at 10.2% of float with 4.1 days to cover, indicating significant bearish positioning against the stock.
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Full company profile →Short Interest
10.2%
4.1 days to cover
Driehaus Capital OLMA Position History
Frequently Asked Questions
Does Driehaus Capital own OLMA?
No. Driehaus Capital exited their position in Olema Pharmaceuticals, Inc. (OLMA) in Q4 2023. They previously held the stock for 3 quarters.
How many hedge funds own OLMA?
10 specialist biotech hedge funds currently hold OLMA, including BVF Partners, Cormorant Asset Management, RA Capital Management and 7 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy OLMA?
Driehaus Capital's position in OLMA was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's OLMA position increasing or decreasing?
Driehaus Capital completely exited their OLMA position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
OLMACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →